Celebrex May Have Colon Cancer Protecting Qualities
Main Category: Cancer / Oncology
Also Included In: Arthritis / Rheumatology; Pain / Anesthetics; Clinical Trials / Drug Trials
Article Date: 04 Apr 2006 - 15:00 PDT
| Patient / Public: | ![]() |
4.42 (12 votes) |
| Health Professional: | ![]() |
2.8 (5 votes) |
| Article Opinions: | 0 posts |
New research indicates that controversial Cox-2 inhibitors may protect patients from developing colon cancer, especially in high-risk individuals. Celebrex is a Cox-2 inhibitor.
There has been a great deal of controversy surrounding Cox-2 inhibitors because of their cardiovascular risks. Cox-2 inhibitors are anti-inflammatory drugs (used for pain relief). They are safer for the stomach than most other pain relievers. Vioxx and Bextra were withdrawn from the market. The only Cox-2 inhibitor still available is Celebrex.
Two studies presented at the American Association for Cancer Research, Washington D.C., USA, indicate that these types of drugs may protect people from colon cancer.
APC Study
One study, called APC (Adenoma Prevention with Celecoxib), included 2,000 patients who were high-risk (for developing colon cancer) - some of them were given either 200 or 400 milligrams of Celebrex, twice a day. Others were given a placebo.
One year and three years later the 2,000 patients underwent colonoscopies.
The scientists found that among the patients given Celebrex, the incidence of at least one benign tumor was 45% lower (than the placebo group). Also, the Celebrex group had a 65% lower chance of developing more serious conditions, such as invasive cancer. As the patients had a 100% to 200% higher chance of developing serious cardiovascular problems the study was stopped early.
PreSAP Study
This study, called Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP), examined how effective Celebrex might be in protecting patients from sporadic colorectal adenomas.
1,561 patients, selected randomly, were either given 400 milligrams of Celebrex, once a day, or a placebo. All the patients had undergone colorectal polyps removal (all of them). After a follow-up three years later, the Celebrex group had a significantly lower incidence of polyps when compared to the placebo group.
In both trials all participants were given aspirin.
Written by: Christian Nordqvist
Editor: Medical News Today
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2009 MediLexicon International Ltd |




